1. bookVolume 29 (2021): Issue 2 (April 2021)
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Vaginal candidiasis in Konya area: Etiology, risk factors, virulence patterns, and antifungal susceptibility

Published Online: 27 Apr 2021
Page range: 201 - 215
Received: 08 Oct 2020
Accepted: 14 Jan 2021
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Vulvovaginal candidiasis (VVC), a common genital tract infection, is known to affect millions of women worldwide. In this study, it was aimed to determine the prevalence, virulence, possible risk factors and antifungal susceptibility model of Candida species. Vaginal swab samples were taken from patients aged 18 years and older who presented to the gynecology outpatient clinic with signs and symptoms suggestive of vulvovaginitis. Demographic data were recorded using a questionnaire. Standard microbiological methods were used for the identification of the isolates. Broth microdilution method was used to determine the antifungal susceptibility of Candida isolates. Virulence factors of Candida strains were determined by performing proteinase, phospholipase, hemolytic and biofilm activity tests. Sequencing of the isolates identified as Candida were performed using ITS 1-4 primers. Vaginal discharge (OR: 3.365; 95% CI: 1.595-7.101), burning complaint (OR: 9.098; 95% CI: 2.284-36.232) and history of allergy (OR: 3.396; 95% CI: 0.968) were risk factors. The results showed that the most common isolated strain was Candida albicans (57%). It was found that the prevalence of C. glabrata remained at 26%, 44 of the C. albicans isolates presented proteinase, 35 had phospholipase, 47 had biofilm, and 47 had hemolytic activity. In this study, susceptible dose-dependent and resistant rates of all Candida strains were found for fluconazole as 9% and 16%, respectively. Host and organism-related factors should be considered in the clinical treatment of VVC, and continuous monitoring of changes in the prevalence of Candida species and susceptibility rates is required for effective antifungal therapy.

Keywords

1. Balcı O, Çapar M. Vaginal enfeksiyonlar. Turk J Obstet Gynecol Der Derg 2005;2(5):14-20.Search in Google Scholar

2. Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol 2016; 42(6):905-27. DOI: 10.3109/1040841X.2015.1091805Search in Google Scholar

3. Bostănaru A, Roșca I, Minea B, Năstasă V, Foia L, Marincu I, et al. Genotype comparison of Candida albicans isolates from different clinical samples. Revista Romana de Medicina de Laborator 2019; 27(3). 327-32. DOI: 10.2478/rrlm-2019-0027Search in Google Scholar

4. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol 2004;104(5):926-30. DOI: 10.1097/01.AOG.0000140687.51048.73Search in Google Scholar

5. Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis 2014;33(5):673-88. DOI: 10.1007/s10096-013-2009-3Search in Google Scholar

6. Naglik JR, Challacombe SJ, Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003;67(3):400-28. DOI: 10.1128/MMBR.67.3.400-428.2003Search in Google Scholar

7. Nagashima M, Yamagishi Y, Mikamo H. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis. J Infect Chemother 2016;22(2):124-6. DOI: 10.1016/j.jiac.2015.08.008Search in Google Scholar

8. Sobel JD. Vulvovaginal candidosis. Lancet 2007;369(9577):1961-71. DOI: 10.1016/S0140-6736(07)60917-9Search in Google Scholar

9. Apalata T, Longo-Mbenza B, Sturm A, Carr W, Mood-ley P. Factors associated with symptomatic vulvovaginal candidiasis: a study among women attending a primary healthcare clinic in Kwazulu-Natal, South Africa. Ann Med Health Sci Res 2014;4(3):410-6. DOI: 10.4103/2141-9248.133470Search in Google Scholar

10. Amouri I, Sellami H, Borji N, Abbes S, Sellami A, Cheikhrouhou F, et al. Epidemiological survey of vulvovaginal candidosis in Sfax, Tunisia. Mycoses 2011;54(5):e499-e505. DOI: 10.1111/j.1439-0507.2010.01965.xSearch in Google Scholar

11. Romeo O, Criseo G. Candida africana and its closest relatives. Mycoses 2011;54:475-86. DOI: 10.1111/j.1439-0507.2010.01939.xSearch in Google Scholar

12. Marot-Leblond A, Nail-Billaud S, Pilon F, Beucher B, Poulain D, Robert R. Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test. J Clin Microbiol 2009;47(12):3821-5. DOI: 10.1128/JCM.01168-09Search in Google Scholar

13. Staib F. Serum-proteins as nitrogen source for yeast-like fungi. J Med Vet Mycol 1966;4(3):187-93. DOI: 10.1080/00362176685190421Search in Google Scholar

14. Gültekin B, Eyigör M, Tiryaki Y, Kırdar S, Aydın N. Kan kültürlerinden izole edilen Candida suşlarında antifungal duyarlılığın ve bazı virülans faktörlerinin araştırılması ve RAPD-PCR ile genotiplendirilmesi. Mikrobiyol Bul 2011;45(2):306-17.Search in Google Scholar

15. Price MF, Wilkinson ID, Gentry LO. Plate method for detection of phospholipase activity in Candida albicans. J Med Vet Mycol 1982;20(1):7-14. DOI: 10.1080/00362178285380031Search in Google Scholar

16. Yenişehirli G, Bulut Y, Tuncoglu E. Phospholipase, proteinase and hemolytic activities of Candida albicans isolates obtained from clinical specimens. Mikrobiyol Bul 2010;44(1):71-7.Search in Google Scholar

17. Luo G, Samaranayake LP, Yau JY. Candida species exhibit differential in vitro hemolytic activities. J Clin Microbiol 2001;39(8):2971-4. DOI: 10.1128/JCM.39.8.2971-2974.2001Search in Google Scholar

18. Branchini M, Pfaller M, Rhine-Chalberg J, Frempong T, Isenberg H. Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis. J Clin Microbiol 1994;32(2):452-6. DOI: 10.1128/JCM.32.2.452-456.1994Search in Google Scholar

19. Wayne P. Reference method for brothdilution anti¬-fungal susceptibility testing of yeasts. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; (Approved standard. M27-S3). Allured Publishing Corporation: Carol Stream, IL, USA; 2008.Search in Google Scholar

20. Wayne P. Reference method for broth dilution anti¬fungal susceptibility testing of yeasts; fourth informational supplement. Wayne: Clinical and Laboratory Standards Institute; (Document M27-S4). Allured Publishing Corporation: Carol Stream, IL, USA; 2012.Search in Google Scholar

21. Pfaller M, Espinel-Ingroff A, Boyken L, Hollis R, Kroeger J, Messer S, et al. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values. J Clin Microbiol 2011;49(3):845-50. DOI: 10.1128/JCM.02441-10Search in Google Scholar

22. Alfouzan W, Dhar R, Ashkanani H, Gupta M, Rachel C, Khan ZU. Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait. J Mycol Med 2015;25(1):23-8 DOI: 10.1016/j.mycmed.2014.10.021Search in Google Scholar

23. Mtibaa L, Fakhfakh N, Kallel A, Belhadj S, Salah NB, Bada N, et al. Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. J Mycol Med 2017;27(2):153-8. DOI: 10.1016/j.mycmed.2017.01.003Search in Google Scholar

24. Maraki S, Mavromanolaki VE, Stafylaki D, Nioti E, Hamilos G, Kasimati A. Epidemiology and antifungal susceptibility patterns of Candida isolates from Greek women with vulvovaginal candidiasis. Mycoses 2019;62(8):692-7. DOI: 10.1111/myc.12946Search in Google Scholar

25. Makanjuola O, Bongomin F, Fayemiwo SA. An update on the roles of non-albicans Candida species in vulvovaginitis. JFOUCU 2018;4(4):121. DOI: 10.3390/jof4040121Search in Google Scholar

26. Siddiqui R. Clinical patterns and risk factors of vulvo-vaginal candidiasis among women of reproductive age attending a tertiary hospital in central India. Stamford J Microbiol 2019;9(1):27-31. DOI: 10.3329/sjm. v9i1.45655Search in Google Scholar

27. Narayankhedkar A, Hodiwala A, Mane A. Clinicoetio-logical characterization of infectious vaginitis amongst women of reproductive age group from Navi Mumbai, India. J Sex Transm Dis 2015;2015:817092. DOI: 10.1155/2015/817092Search in Google Scholar

28. Altayyar IA, Alsanosi AS, Osman NA. Prevalence of vaginal candidiasis among pregnant women attending different gynecological clinic at South Libya. Eur J Exp Biol 2016;6(3):25-9.Search in Google Scholar

29. Guzel AB, Ilkit M, Akar T, Burgut R, Demir SC. Evaluation of risk factors in patients with vulvovaginal candidiasis and the value of chromID Candida agar versus CHROMagar Candida for recovery and presumptive identification of vaginal yeast species. Med Mycol 2011;49(1):16-25. DOI: 10.3109/13693786.2010.497972Search in Google Scholar

30. Guzel AB, Ilkit M, Burgut R, Urunsak IF, Ozgunen FT. An evaluation of risk factors in pregnant women with Candida vaginitis and the diagnostic value of simultaneous vaginal and rectal sampling. Mycopathologia 2011;172(1):25-36. DOI: 10.1007/s11046-011-9392-zSearch in Google Scholar

31. Güzel AB, Aydın M, Meral M, Kalkancı A, Ilkit M. Clinical characteristics of Turkish women with Candida krusei vaginitis and antifungal susceptibility of the C. krusei isolates. Infect Dis Obstet Gynecol 2013;2013:698736. DOI: 10.1155/2013/698736Search in Google Scholar

32. Yamamoto T, Nohara K, Uchida K, Yamaguchi H. Purification and characterization of secretory proteinase of Candida albicans. Microbiol Immunol 1992;36(6):637-41. DOI: 10.1111/j.1348-0421.1992.tb02064.xSearch in Google Scholar

33. Fotedar R, Al-Hedaithy S. Comparison of phospholipase and proteinase activity in Candida albicans and C. dubliniensis. Mycoses 2005;48(1):62-7. DOI: 10.1111/j.1439-0507.2004.01057.xSearch in Google Scholar

34. Udayalaxmi SJ, D’Souza D. Comparison between virulence factors of Candida albicans and non-albicans species of Candida isolated from genitourinary tract. J Clin Diagn Res 2014;8(11):15-7.Search in Google Scholar

35. Morschhäuser J. Regulation of white-opaque switching in Candida albicans. Med Microbiol Immunol 2010;199(3):165-72. DOI: 10.1007/s00430-010-0147-0Search in Google Scholar

36. Dabiri S, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Comparative analysis of proteinase, phospholipase, hydrophobicity and biofilm forming ability in Candida species isolated from clinical specimens. J Mycol Med 2018;28(3):437-42. DOI: 10.1016/j.mycmed.2018.04.009Search in Google Scholar

37. Seneviratne CJ, Rajan S, Wong SS, Tsang DN, Lai CK, Samaranayake LP, et al. Antifungal susceptibility in serum and virulence determinants of Candida bloodstream isolates from Hong Kong. Front Microbiol 2016;7:216. DOI: 10.3389/fmicb.2016.00216Search in Google Scholar

38. Kalkanci A, Güzel A, Jabban I, Aydin M, Ilkit M, Kuştimur S. Candida vaginitis in non-pregnant patients: a study of antifungal susceptibility testing and virulence factors. J Obstet Gynaecol 2013;33(4):378-83. DOI: 10.3109/01443615.2013.767323Search in Google Scholar

39. Gamarra S, Morano S, Dudiuk C, Mancilla E, Nardin ME, de los Angeles Méndez E, et al. Epidemiology and antifungal susceptibilities of yeasts causing vulvovaginitis in a teaching hospital. Mycopathologia 2014;178(3-4):251-8. DOI: 10.1007/s11046-014-9780-2Search in Google Scholar

40. Subramanya SH, Baral BP, Sharan NK, Nayak N, Metok Y, Sathian B, et al. Antifungal susceptibility and phenotypic virulence markers of Candida species isolated from Nepal. BMC Res Notes 2017;10(1):543. DOI: 10.1186/s13104-017-2852-xSearch in Google Scholar

41. Morris AJ, Rogers K, McKinney WP, Roberts SA, Freeman JT. Antifungal susceptibility testing results of New Zealand yeast isolates, 2001-2015: Impact of recent CLSI breakpoints and epidemiological cut-off values for Candida and other yeast species. J Glob Antimicrob Resist 2018;14:72-7. DOI: 10.1016/j.jgar.2018.02.014Search in Google Scholar

42. Chong PP, Hadi SRA, Lee YL, Phan CL, Tan BC, Ng KP, et al. Genotyping and drug resistance profile of Candida spp. in recurrent and one-off vaginitis, and high association of non-albicans species with non-pregnant status. Infect Genet Evol 2007;7(4):449-56. DOI: 10.1016/j.meegid.2007.01.004Search in Google Scholar

43. Donders GG, Mertens I, Bellen G, Pelckmans S. Self-elimination of risk factors for recurrent vaginal candidosis. Mycoses. 54(1):39-45. DOI: 10.1111/j.1439-0507.2009.01754.xSearch in Google Scholar

44. Pesewu GA, Feglo PK, Boateng RK, Fayemiwo SA. Prevalence and Antifungal Susceptibility Pattern of Candida Isolates from Women with Recurrent Vulvovaginal Candidiasis in Ghana - A Review of Laboratory Reports. Research Square; 2020. DOI: 10.21203/rs.3.rs-33278/v1Search in Google Scholar

45. Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol 2014;52(3):994-7. DOI: 10.1128/JCM.03044-13Search in Google Scholar

46. Arikan-Akdagli S, Gülmez D, Doğan Ö, Çerikçioğlu N, Dereli MD, Birinci A, et al. First multicentre report of in vitro resistance rates in candidaemia isolates in Turkey. J Glob Antimicrob Resist 2019;18:230-4. DOI: 10.1016/j.jgar.2019.04.003Search in Google Scholar

47. Mahmoudabadi AZ, Rezaei-Matehkolaei A, Ghanavati F. The susceptibility patterns of Candida species isolated from urine samples to posaconazole and caspofungin. Jundishapur J Microbiol 2015;8(3):e24298. DOI: 10.5812/jjm.24298Search in Google Scholar

48. Etiz P, Kibar F, Ekenoğlu Y, Yaman A. Kan kültürlerinden izole edilen Candida türlerinin dağılımının ve anti-fungal duyarlılıklarının retrospektif olarak değerlendirilmesi. Ankem Derg 2015;29(3):105-13.Search in Google Scholar

49. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn Microbiol Infect Dis 2011;69(1):45-50. DOI: 10.1016/j.diagmicrobio.2010.08.013Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo